Don't want to miss the best from Business Standard?
Cadila Healthcare rose 1.86% to Rs 1,692.10 at 9:43 IST on BSE after the company said it has purchased 50% shares of Zydus BSV Pharma from Bharat Serums and Vaccines and now Zydus BSV has become 100% subsidiary of Cadila Healthcare.
The announcement was made after market hours yesterday, 26 March 2015.
Meanwhile, the S&P BSE Sensex was up 46.85 points or 0.17% at 27,504.43.
On BSE, so far 6,020 shares were traded in the counter as against average daily volume of 21,000 shares in the past two weeks.
The stock hit a high of Rs 1,721 and a low of Rs 1,686.65 so far during the day.
Also Read
On a consolidated basis, Cadila Healthcare's net profit rose 51.6% to Rs 281.91 crore on 17.5% growth in net sales to Rs 2159.54 crore in Q3 December 2014 over Q3 December 2013.
Cadila Healthcare is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Powered by Capital Market - Live News
